European Union - English - EMA (European Medicines Agency)

glaxo group limited  - retigabine - epilepsy - antiepileptics, - trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - retigabine - tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - retigabine - tablet - 400mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - retigabine - tablet - 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - retigabine - tablet - 200mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - retigabine - tablet - 100mg

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - retigabine 100 mg; retigabine 50 mg - film coated tablets - retigabine - trobalt is indicated as adjunctive treatment of drug-resistant partial onset seizures with or without secondary generalization in patients aged 18 -65 years with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - retigabine - tablet, film coated - 100.0 mg

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - retigabine - tablet, film coated - 200.0 mg

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - retigabine - tablet, film coated - 300.0 mg